Surgical Oncology

Medicine & Life Sciences

1. Adenocarcinoma 55%
2. Adjuvant Chemotherapy 8%
3. Adrenocortical Carcinoma 21%
4. Antibodies 8%
5. Antigens 6%
6. Apoptosis 6%
7. Blood Vessels 15%
8. Breast 24%
9. Breast Neoplasms 48%
10. Cancer-Associated Fibroblasts 6%
11. Carcinoma 13%
12. Cholangiocarcinoma 15%
13. Clinical Trials 8%
14. Collagen 7%
15. Colonic Neoplasms 12%
16. Colorectal Neoplasms 17%
17. Confidence Intervals 11%
18. Cysteine 13%
19. Cytoreduction Surgical Procedures 7%
20. Databases 9%
21. Discoidin Domain Receptor 1 11%
22. Dissection 7%
23. Drug Therapy 25%
24. Endothelial Cells 7%
25. Extracellular Matrix 7%
26. Fibrosis 17%
27. gemcitabine 6%
28. Genes 6%
29. Growth 18%
30. Guidelines 14%
31. Hepatectomy 14%
32. Hepatocellular Carcinoma 67%
33. Heterografts 12%
34. Incidence 8%
35. Integrins 6%
36. Interleukin-10 6%
37. Klatskin Tumor 6%
38. Liver 67%
39. Liver Diseases 8%
40. Liver Neoplasms 19%
41. Liver Transplantation 7%
42. Lung 7%
43. Lung Neoplasms 6%
44. Lymph Node Excision 17%
45. Lymph Nodes 17%
46. Lymphangiogenesis 7%
47. Margins of Excision 8%
48. Melanoma 10%
49. Morbidity 8%
50. Mortality 14%
51. Mutation 9%
52. Neoadjuvant Therapy 7%
53. Neoplasm Metastasis 73%
54. Neoplasms 100%
55. Neuroendocrine Tumors 18%
56. Non-Small Cell Lung Carcinoma 7%
57. Odds Ratio 11%
58. Oncologists 16%
59. Operating Rooms 7%
60. Palliative Care 10%
61. Pancreas 10%
62. Pancreatectomy 12%
63. Pancreatic Neoplasms 52%
64. Pancreaticoduodenectomy 26%
65. Pathologists 7%
66. Peptoids 10%
67. Peritoneal Diseases 9%
68. Peritoneal Neoplasms 20%
69. Phosphatidylserines 13%
70. Physicians 7%
71. Population 7%
72. Practice Guidelines 7%
73. Proteins 13%
74. Radiofrequency Ablation 12%
75. Radiologists 8%
76. Radiotherapy 9%
77. Randomized Controlled Trials 6%
78. Rectal Neoplasms 9%
79. Recurrence 24%
80. Robotics 9%
81. Safety 7%
82. Safety-net Providers 9%
83. Sarcoma 13%
84. Segmental Mastectomy 8%
85. Sentinel Lymph Node 17%
86. Sentinel Lymph Node Biopsy 6%
87. Spiral Computed Tomography 7%
88. Stomach 10%
89. Stomach Neoplasms 16%
90. Surgeons 30%
91. Survival 64%
92. T-Lymphocytes 10%
93. Therapeutics 33%
94. Tumor Burden 6%
95. Tumor Microenvironment 7%
96. Ultrasonography 7%
97. Vascular Endothelial Growth Factor A 38%
98. Vascular Endothelial Growth Factor Receptor 9%
99. Vascular Endothelial Growth Factor Receptor-2 14%
100. Wounds and Injuries 11%